Overview
2015Founded1
Compare with Agios Pharmaceuticals, Rockwell Medical Inc. or Lexicon Pharmaceuticals, or pick any stock.
- TickerALPN on NASDAQ1
- Industrypharmaceutical industry1
- HeadquartersBoulder, United States1
- Websitewww.alpineimmunesciences.com
- Legal formDelaware corporation1
- Incorporated inDE4
- Business address600 Stewart St., Ste. 1503, Seattle, Wa 981014
- LEI5493000845S6RLSDWJ403
- StatusActive3
- LEI statusLapsed (not renewed)3
- Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States3
- Registered withDivision of Corporations, Department of State, 43212113
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2023
-75.2%Operating margin5
-54.7%Net margin5
95.8%Revenue growth, 20235
-9.8%Return on equity5
-$79.5MFree cash flow5
Where the money goes
Where each dollar of revenue went, fiscal 2023
- Research and development100¢$80.9M
- Interest0¢$98.0K
- Income tax0¢$103.0K
Out of $58.9M in revenue.5 The company lost money this year.
Financial statements
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.7M6 | $705.0K7 | $1.7M8 | $9.3M9 | $23.4M5 | $30.1M5 | $58.9M5 |
| Research and development | $10.6M6 | $29.0M7 | $35.8M8 | $27.2M9 | $58.7M5 | $70.2M5 | $80.9M5 |
| Operating expenses | $73.3M5 | $88.2M5 | $103.1M5 | ||||
| Operating income | -$15.0M6 | -$37.8M7 | -$43.6M8 | -$28.7M9 | -$49.9M5 | -$58.1M5 | -$44.2M5 |
| Interest | $152.0K6 | $319.0K7 | $338.0K8 | $775.0K9 | $816.0K5 | $476.0K5 | $98.0K5 |
| Income before tax | -$50.4M5 | -$55.4M5 | -$32.1M5 | ||||
| Income tax | -$200.0K6 | -$366.0K7 | $08 | -$6.0K9 | -$87.0K5 | $2.3M5 | $103.0K5 |
| Net income | -$7.8M6 | -$36.5M7 | -$41.9M8 | -$27.9M9 | -$50.3M5 | -$57.8M5 | -$32.2M5 |
| Earnings per share | -$2.288 | -$1.349 | -$1.985 | -$1.735 | -$0.645 | ||
| Earnings per share (diluted) | -$2.288 | -$1.349 | -$1.985 | -$1.735 | -$0.645 | ||
| Shares (weighted, basic) | 25.5M shares5 | 33.4M shares5 | 50.0M shares5 | ||||
| Shares (weighted, diluted) | 25.5M shares5 | 33.4M shares5 | 50.0M shares5 |
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Cash | $8.0M13 | $10.7M6 | $16.1M7 | $35.0M8 | $67.9M9 | $13.4M5 | $43.9M5 |
| Receivables | $25.0M9 | $392.0K5 | $167.0K5 | ||||
| Current assets | $82.5M13 | $53.5M6 | $42.3M7 | $107.1M8 | $192.0M9 | $241.0M5 | $330.0M5 |
| Property, plant and equipment | $1.7M9 | $1.6M5 | $1.5M5 | ||||
| Total assets | $85.2M13 | $54.9M6 | $54.1M7 | $144.1M8 | $255.9M9 | $286.7M5 | $379.9M5 |
| Accounts payable | $3.3M9 | $4.3M5 | $3.6M5 | ||||
| Short-term debt | $4.6M9 | $3.4M5 | $05 | ||||
| Current liabilities | $1.9M13 | $8.1M6 | $8.7M7 | $41.2M8 | $69.8M9 | $58.0M5 | $42.0M5 |
| Long-term debt | $4.0M13 | $2.2M6 | $4.5M7 | $7.6M8 | $3.4M9 | $09 | |
| Total liabilities | $6.3M13 | $10.3M6 | $24.6M7 | $81.9M8 | $135.0M9 | $107.3M5 | $51.9M5 |
| Retained earnings | -$166.2M9 | -$224.0M5 | -$256.1M5 | ||||
| Shareholders’ equity | $78.9M7 | $44.6M8 | $29.5M9 | $62.2M5 | $120.9M5 | $179.4M5 | $327.9M5 |
| Shares outstanding | 13.8M shares13 | 13.9M shares6 | 18.6M shares7 | 23.8M shares8 | 30.2M shares9 | 46.0M shares5 | 60.3M shares5 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -$16.6M6 | -$28.4M7 | -$35.3M8 | $30.1M9 | -$15.2M5 | -$43.8M5 | -$79.0M5 |
| Stock-based compensation | $6.2M5 | $9.6M5 | $10.6M5 | ||||
| Capital spending | $586.0K6 | $495.0K7 | $821.0K8 | $802.0K9 | $118.0K5 | $412.0K5 | $487.0K5 |
| Free cash flow | -$17.2M | -$28.9M | -$36.2M | $29.3M | -$15.4M | -$44.2M | -$79.5M |
| Cash from investing | -$52.5M5 | -$113.3M5 | -$55.6M5 | ||||
| Cash from financing | $100.8M5 | $102.7M5 | $165.1M5 |
Corporate structure
Alpine Immune Sciences sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Alpine Immune Sciences
- GREAT POINT PARTNERS LLC Filed SC 13G/A on Alpine Immune Sciences, latest Nov 14, 2024 (4 filings since Sep 30, 2022)
- Decheng Capital China Life Sciences USD Fund III, L.P. Filed SC 13D/A on Alpine Immune Sciences, latest May 21, 2024 (4 filings since Sep 27, 2022)
- Frazier Life Sciences VIII, L.P. Filed SC 13D/A on Alpine Immune Sciences, latest May 21, 2024 (4 filings since Feb 15, 2022)
- BlackRock Filed SC 13G/A on Alpine Immune Sciences, latest Mar 7, 2024 (2 filings since Feb 2, 2024)
- Cormorant Asset Management, LP Filed SC 13G/A on Alpine Immune Sciences, latest Feb 14, 2024 (2 filings since Oct 23, 2023)
- Lynx1 Capital Management LP Filed SC 13G/A on Alpine Immune Sciences, latest Feb 14, 2024 (3 filings since Apr 22, 2022)
- Omega Fund VI, L.P. Filed SC 13G/A on Alpine Immune Sciences, latest Feb 14, 2024 (3 filings since Feb 14, 2022)
- Paradigm Biocapital Advisors LP Filed SC 13G/A on Alpine Immune Sciences, latest Feb 14, 2024 (3 filings since Oct 3, 2022)
- RA CAPITAL MANAGEMENT, L.P. Filed SC 13G/A on Alpine Immune Sciences, latest Feb 14, 2024 (3 filings since Oct 3, 2022)
- ORBIMED ADVISORS LLC Filed SC 13D/A on Alpine Immune Sciences, latest Dec 29, 2023 (4 filings since Nov 12, 2021)
- Alpine ImmunoSciences, L.P. Filed SC 13D/A on Alpine Immune Sciences, latest Nov 14, 2023 (2 filings since Sep 27, 2022)
- Avidity Partners Management LP Filed SC 13G/A on Alpine Immune Sciences, latest Feb 14, 2023 (2 filings since Feb 14, 2022)
- Alpine Immune Sciences Boulder, Colorado, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
Leadership
Who has led Alpine Immune Sciences, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
20202025
- Chief executive officerMitchell Gold Jul 26, 2017 to May 20, 202414
- Chief executive officerJon Congleton Jun 16, 2015 to Sep 14, 201615
- ChairMitchell Gold Jul 26, 2017 to May 20, 202414
- PresidentStanford L. Peng Jan 27, 2020 to Jan 27, 202016
- PresidentJay Venkatesan Jul 26, 2017 to Jan 4, 201817
- PresidentJon Congleton Jun 16, 2015 to Sep 14, 201615
- Chief financial officerJames Paul Rickey Jul 26, 2017 to Jan 6, 202218
- Chief operating officerJanice Troha Jun 16, 2015 to May 9, 201719
Board members and other officers (28)
- Chief Accounting OfficerUlrich Martin Fuhs Apr 5, 2024 to May 20, 202420
- OfficerJames Paul Rickey Jan 5, 2023 to May 20, 202421
- Chief Business OfficerRemy Durand Apr 27, 2023 to May 20, 202422
- Chief Medical OfficerWolfgang Dummer Oct 4, 2023 to Oct 4, 202323
- Chief Medical OfficerAndrew Seth Sandler Aug 18, 2022 to Jan 5, 202324
- Chief Medical OfficerZelanna Goldberg Jun 2, 2021 to Jun 2, 202125
- OfficerMark James Litton Aug 8, 2018 to Feb 8, 201926
- OfficerStanford L. Peng Jul 26, 2017 to May 20, 202427
- OfficerDavid Malcom Rodman Apr 22, 2016 to Jan 5, 201728
- VP of Research & DiscoverySherif Gabriel Jun 16, 2015 to Sep 15, 201529
- VP of Clinical R & D & Med DirSteven Shoemaker Jun 16, 2015 to Sep 15, 201530
- Board memberJorn Drappa Jul 19, 2022 to May 20, 202431
- Board memberNatasha Hernday Dec 11, 2020 to May 20, 202432
- Board memberXiangmin Cui Jan 23, 2019 to May 20, 202433
- Board memberChristopher Peetz Apr 24, 2018 to May 20, 202434
- Board memberJames N. Topper Jul 26, 2017 to May 20, 202435
- Board memberJay Venkatesan Jul 26, 2017 to Jul 19, 202217
- Board memberPeter A. Thompson Jul 26, 2017 to May 20, 202436
- Board memberSamuel D. Isaly Jul 26, 2017 to Jul 26, 201737
- Board memberPaul J. Sekhri Mar 2, 2016 to Jan 6, 202038
- Board memberJames E. Flynn Sep 14, 2016 to Sep 14, 201639
- Board memberCynthia Smith Nov 4, 2016 to Nov 4, 201640
- Board memberEvan Loh Jun 16, 2015 to Sep 14, 201641
- Board memberHoward P. Furst Jun 16, 2015 to Sep 14, 201642
- Board memberJohn R. Moore Jun 16, 2015 to Sep 14, 201643
- Board memberJon Congleton Jun 16, 2015 to Sep 14, 201615
- Board memberJonathan S. Leff Jun 16, 2015 to Sep 15, 201544
- Board memberRobert E. Conway Jun 16, 2015 to May 20, 202445
Timeline
- May 20, 20248-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer46
- May 9, 20248-K Results of operations; Regulation FD disclosure47
- Apr 10, 20248-K Entered a material agreement; Other events48
- Apr 5, 20248-K Executive or director change49
- Mar 18, 20248-K Results of operations; Regulation FD disclosure50
- Feb 7, 20248-K Unregistered sale of shares; Other events51
- Jan 5, 20248-K Executive or director change52
- Dec 21, 20238-K Entered a material agreement53
- Nov 14, 20238-K Results of operations; Regulation FD disclosure54
- Nov 8, 20238-K Entered a material agreement; Other events55
- Nov 6, 20238-K Results of operations56
- Nov 2, 20238-K Other events57
- Jul 26, 2017New chief executive Mitchell Gold becomes CEO14
- Jun 16, 2015New chief executive Jon Congleton becomes CEO15
- 2015Founded Founded1
Calendar
When it reported results
- May 9, 2024Reported quarterly or annual results47
- Mar 18, 2024Reported quarterly or annual results50
- Nov 14, 2023Reported quarterly or annual results54
- Nov 6, 2023Reported quarterly or annual results56
- Aug 14, 2023Reported quarterly or annual results58
- May 11, 2023Reported quarterly or annual results59
- Mar 23, 2023Reported quarterly or annual results60
- Nov 14, 2022Reported quarterly or annual results61
Drug trials and FDA: recently
- Aug 12, 2026Phase 1/2 trial completed Phase 1/2 trial of Povetacicept in Idiopathic Thrombocytopenic Purpura: primary completion Aug 12, 2026, no results posted yet (ClinicalTrials.gov NCT05757570).62
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar
Filings
232 filings to the SEC since October 2021: 4 annual reports, 8 quarterly reports, 33 major events, 83 insider forms, 39 large holders, 65 other. The latest 20:
- Nov 14, 2024SC 13G/A EDGAR
- May 30, 202415-12G EDGAR
- May 23, 2024EFFECT EDGAR
- May 23, 2024EFFECT EDGAR
- May 21, 2024SC 13D/A EDGAR
- May 21, 2024SC 13D/A EDGAR
- May 20, 20244 EDGAR
- May 20, 20244 EDGAR
- May 20, 20244 EDGAR
- May 20, 20244 EDGAR
- May 20, 20244 EDGAR
- May 20, 20244 EDGAR
- May 20, 20244 EDGAR
- May 20, 20244 EDGAR
- May 20, 20244 EDGAR
- May 20, 20244 EDGAR
- May 20, 20244 EDGAR
- May 20, 20244 EDGAR
- May 20, 2024S-8 POS EDGAR
- May 20, 2024S-8 POS EDGAR
The 232 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- GREAT POINT PARTNERS LLCSC 13G/A, 4 filings Sep 30, 2022 to Nov 14, 202463
- Decheng Capital China Life Sciences USD Fund III, L.P.SC 13D/A, 4 filings Sep 27, 2022 to May 21, 202464
- Frazier Life Sciences VIII, L.P.SC 13D/A, 4 filings Feb 15, 2022 to May 21, 202465
- BlackRockSC 13G/A, 2 filings Feb 2, 2024 to Mar 7, 202466
- Cormorant Asset Management, LPSC 13G/A, 2 filings Oct 23, 2023 to Feb 14, 202467
- Lynx1 Capital Management LPSC 13G/A, 3 filings Apr 22, 2022 to Feb 14, 202468
- Omega Fund VI, L.P.SC 13G/A, 3 filings Feb 14, 2022 to Feb 14, 202469
- Paradigm Biocapital Advisors LPSC 13G/A, 3 filings Oct 3, 2022 to Feb 14, 202470
- RA CAPITAL MANAGEMENT, L.P.SC 13G/A, 3 filings Oct 3, 2022 to Feb 14, 202471
- ORBIMED ADVISORS LLCSC 13D/A, 4 filings Nov 12, 2021 to Dec 29, 202372
- Alpine ImmunoSciences, L.P.SC 13D/A, 2 filings Sep 27, 2022 to Nov 14, 202373
- Avidity Partners Management LPSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202374
- BIOTECHNOLOGY VALUE FUND L PSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202375
- Decheng Capital Management III (Cayman), LLCSC 13G, 1 filing Feb 14, 202276
SEC filer profile
How Alpine Immune Sciences is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
Links
- Websitewww.alpineimmunesciences.com1
- X (Twitter)x.com/AlpineImmuneSci1
- LinkedInwww.linkedin.com/company/alpine-immune-sciences1
- WikidataQ104481262
- SEC EDGARCIK 1632083
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARStanford L. Peng, President
- 17SEC EDGARJay Venkatesan, President
- 18
- 19
- 20
- 21SEC EDGARJames Paul Rickey, Officer
- 22SEC EDGARRemy Durand, Chief Business Officer
- 23
- 24
- 25
- 26SEC EDGARMark James Litton, Officer
- 27SEC EDGARStanford L. Peng, Officer
- 28SEC EDGARDavid Malcom Rodman, Officer
- 29
- 30
- 31SEC EDGARJorn Drappa, Board member
- 32SEC EDGARNatasha Hernday, Board member
- 33SEC EDGARXiangmin Cui, Board member
- 34SEC EDGARChristopher Peetz, Board member
- 35SEC EDGARJames N. Topper, Board member
- 36SEC EDGARPeter A. Thompson, Board member
- 37SEC EDGARSamuel D. Isaly, Board member
- 38SEC EDGARPaul J. Sekhri, Board member
- 39SEC EDGARJames E. Flynn, Board member
- 40SEC EDGARCynthia Smith, Board member
- 41SEC EDGAREvan Loh, Board member
- 42SEC EDGARHoward P. Furst, Board member
- 43SEC EDGARJohn R. Moore, Board member
- 44SEC EDGARJonathan S. Leff, Board member
- 45SEC EDGARRobert E. Conway, Board member
- 46
- 47
- 48
- 49SEC EDGARExecutive or director change
- 50
- 51
- 52SEC EDGARExecutive or director change
- 53SEC EDGAREntered a material agreement
- 54
- 55
- 56SEC EDGARResults of operations
- 57SEC EDGAROther events
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76